Cancers

3

Review clinical trials related to Cancers. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Safety and Pharmacokinetics of NM6603 in Chinese Patients With Advanced Solid Tumors

This study is to assess the MTD and PK of NM6603 in adult patients with advanced solid tumors.

Participants needed: 30
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: NucMito Pharmaceuticals Co. Ltd.Updated: Jan 14, 2026Locations: 3
Eligibility criteria

Advanced solid tumors (primarily advanced colorectal cancer or triple-negative b... [+15]

Known hypersensitivity to NM6603 or its components [+25]

Status: Recruiting

Ovarian Tissue Cryopreservation in Pre-Pubertal (OTC-Pre Pubertal)

The purpose of this study is to safely remove ovarian tissue in pre-pubertal pediatric patients, who are at risk for infertility from their medical treatment, for freezing for future restoration of fertility and hormone function.

Participants needed: 250
Trial details
Age: Up to 11Biological sex: FemaleType: ObservationalSponsor: Erin RowellUpdated: Nov 18, 2024Locations: 1Duration: 10 Years
Eligibility criteria

Pre- Pubertal Individual [+4]

Patients with no anticipated oncologic therapies [+5]

Status: Not yet recruiting

Risk and Clinical Consequences of Low Count Monoclonal B-cell Lymphocytosis (LC MBL)

The aim of this proposal is to identify immune biomarkers, genetic risk, and the clinical consequences of low count monoclonal B-cell lymphocytosis (LC MBL), a common premalignant condition affecting up to 17% of European adults age\>40. LC MBL is a precursor to chronic lymphocytic leukemia (CLL), characterized by a circulating population of clonal B-cells. It is relatively understudied, despite emerging evidence of clinical consequences such as increased risk for life-threatening infections and lymphoid malignancies. Studies reported that male sex, age, family history of CLL, and CLL-susceptibility genetic loci were associated with LC MBL risk. These findings were reported in European ancestry individuals and have not been generalized to other thnicities. This study will provide this missing knowledge using a unique multi-ethnic Israeli population of Jews and Arabs that have one of the highest and lowest age-standardized incidence rates of CLL in the world, respectively, and characterized with different genetic backgrounds.

Participants needed: 1,500
Trial details
Age: 40+Biological sex: AllType: ObservationalSponsor: University of HaifaUpdated: May 16, 2024
Eligibility criteria

Individuals over the age pf 40

Individuals with lymphoproliferative disorder